Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
ZaleplonCat. No. 3655 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: CL 284846 Chemical Name: N-[3-(Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide |
Biological Activity
Non-benzodiazepine agent that acts as an agonist at the benzodiazepine site. Displays hypnotic, anxiolytic, myorelaxant and anticonvulsant activity.Certificate of Analysis / Safety Data Sheet
References
Gaudreault et al (1995) Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. Pharm.Res. 12 1592. PMID: 8592655.
Sanger et al (1996) Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur.J.Pharmacol. 313 35. PMID: 8905326.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Zaleplon, supplier, Benzodiazepine, agonists, GABAA, Receptors, CL284846
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.